SpaceX Q3: When Even The Stars Aren't The Limit

SpaceX posted strong Q3 growth across Space, Connectivity, and Super Intelligence, with SI adjusted EBITDA rising to $4.95 billion from $1.1 billion in the prior quarter. Higher CapEx and R&D underscore the capital-intensive model, while the article argues that a roughly $2 trillion market capitalization leaves no margin of safety and is justified through 2035 only under optimistic assumptions.

Analysis

The key underwriting issue is cash conversion, not headline EBITDA momentum. A sharp segment-level EBITDA increase can support near-term sentiment while capex and R&D absorb the incremental cash; until segment definitions, recurring revenue, and free-cash-flow conversion are verified, extrapolating that run rate risks overstating economic earnings. At a valuation that already discounts exceptional execution, even solid growth may not protect the equity if investment rises faster than monetizable demand.

Over days, momentum may dominate fundamentals. Over 1–3 months, the catalyst is evidence that SI growth persists and converts to cash—not another isolated EBITDA step-up. Over 6–18 months, sustained capital intensity or weaker returns on incremental investment could drive multiple compression; higher real rates would amplify that duration risk. AI infrastructure suppliers could benefit if spending expands, but the article provides no spend breakdown to identify direct beneficiaries.

Contrarian angle: the valuation may be vulnerable, but a valuation argument alone is a poor timing signal if operating momentum continues. A measured underweight is better supported than an outright short absent evidence of slowing growth, deteriorating cash conversion, or a broken catalyst. Reassess if reported free cash flow and segment disclosures demonstrate durable cash generation alongside investment.

Key Decisions for Investors

• Avoid adding to SPCX solely on the reported EBITDA acceleration; first verify SI segment scope, revenue quality, capex/R&D trajectory, and cash conversion in the underlying disclosures.
• For existing exposure, consider a modest trim or underweight rather than an outright short. A defined-risk put spread is only a watch item if listed options are liquid and pricing is acceptable; no price target is supportable from the supplied data.
• Set a 1–3 month review trigger around the next results or disclosures: persistent SI growth with improving free-cash-flow conversion would weaken the cautious thesis; rising investment without corresponding monetizable growth would strengthen it.
• Falsification: reduce the underweight if multiple reporting periods show durable segment earnings and cash generation after investment. Escalate caution if management signals sustained capex/R&D acceleration while growth or cash conversion stalls, or if higher real rates pressure long-duration valuations.